Reducing Dexamethasone Around Docetaxel Infusion

Inclusion Criteria: * Patients with early breast cancer, or advanced breast cancer or prostate cancer patients receiving docetaxel (minimal 3 cycles monotherapy or in the regimen 4xAC \> 4xdocetaxel or 3xFEC\>3xdocetaxel or 6xTAC) * Age ≥18 years * WHO performance status 0-2 * Adequate bone marrow function: white blood cells (WBCs) ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l * Adequate liver function: bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL (\<5 x UNL in case of liver metastases), Alkaline Phosphatase ≤5 x UNL * Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min * Survival expectation must be \> 3 months * Written informed consent according to the local Ethics Committee requirements Exclusion Criteria: * Known hypersensitivity for docetaxel, paclitaxel or other chemotherapeutic agent or products containing polysorbate 80 or an earlier experience of anaphylaxis for food, insect bites, medication or another foreign substance. * Existence of edema of the limbs or trunk or elsewhere localized. * Active second malignancy * Diabetes Mellitus * Serious other diseases such as recent myocardial infarction (last 6 months), clinical signs of cardiac failure or clinically significant arrhythmias * Female patients who are pregnant or breast-feeding * Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent